Tamoxifen Activates Dormant Primordial Follicles in Mouse Ovaries

Reprod Sci. 2022 Dec;29(12):3404-3412. doi: 10.1007/s43032-022-00896-0. Epub 2022 Feb 25.

Abstract

Our previous study found that 17β-estradiol (E2) suppresses primordial follicle activation and growth in cultured mouse ovaries. In this study, we administered tamoxifen, an estrogen receptor antagonist, into the abdominal cavity of mice to clarify the relationship between primordial follicle activation and the physiological concentration of E2 in mouse ovaries. The results showed that tamoxifen promoted primordial follicle activation. Administration of tamoxifen promoted degradation of the extracellular matrix surrounding primordial follicles in the ovaries. Furthermore, tamoxifen decreased the expression of stefin A, an inhibitor of cathepsins that digest some proteins and extracellular matrix, in the ovaries. Mechanical stress produced by the extracellular matrix reportedly suppresses the activation of primordial follicles. The collective results show that tamoxifen can promote primordial follicle activation through the degradation of the extracellular matrix surrounding primordial follicles. Our results indicate that E2 suppresses primordial follicle activation in vivo and that tamoxifen may be useful as a therapeutic agent against infertility.

Keywords: 17β-estradiol; Collagen type IV; Primordial follicle; Tamoxifen.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Estradiol / metabolism
  • Estradiol / pharmacology
  • Female
  • Mice
  • Ovarian Follicle* / metabolism
  • Ovary / metabolism
  • Tamoxifen* / pharmacology

Substances

  • Tamoxifen
  • Estradiol